As part of Baylor Genetics’ commitment to delivering clear, clinically relevant results, the organization has updated the gene content included in its secondary findings analysis for Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES). This update aligns with the most recent American College of Medical Genetics & Genomics (ACMG) Secondary Findings v3.3 list.
What’s Changing
Effective January 12, 2026, three additional genes will be reviewed when secondary findings are opted in to:
- ABCD1 – Adrenoleukodystrophy (OMIM 300100)
- CYP27A1 – Cerebrotendinous xanthomatosis (OMIM 213700)
- PLN – Dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy (OMIM 609909)
No other changes have been made to our secondary findings content, gene list, reporting, or ordering workflows.
What This Means for Healthcare Providers & Patients
- Secondary findings remain optional for WGS and WES.
- Providers who opt-in will automatically receive results based on the updated gene list.
- There is no change to consent requirements, billing, or turnaround time.
For questions about this update, your Baylor Genetics regional account executive is ready to help. You may also contact Client Services at 1-800-411-4363 or info@baylorgenetics.com.
Thank you for your continued partnership and for the care you provide to patients and families every day.
Reference
Lee, K., Abul-Husn, N., et al. ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine. Volume 27. Issue 8, 2025. 101454. ISSN 1098-3600. https://doi.org/10.1016/j.gim.2025.101454.